Skip to content
AnalystLens

IDEXX Laboratories Annual Report, Year Ended Dec 31, 2013

Filing Date
Filed February 18, 2014
Period End
December 31, 2013
Security
IDXX
One revenue dollarkept$0.14
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. FY2016 annual report10-K · Feb ’17Feb ’17
  2. Leadership change8-K · Oct ’19Oct ’19
  3. Material agreement8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Jan ’26Jan ’26

Summary

Summary of the 10-K filed February 18, 2014. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories' FY2013 10-K shows a company that grew revenue 6.5% to $1.377 billiona, with operating income up only 1.6% to $266.8 million, as operating margin compressed from 20.3% to 19.4%.

Growth was led by the Companion Animal Group (CAG), whose revenue rose 7.3% to $1.150 billionb, driven by recurring diagnostic revenue (VetLab consumables, reference laboratory services, and rapid assays). Diluted EPS rose to $3.48 from $3.17, helped by a 4.0 million-share repurchase ($367.8 million) that cut the diluted share count to about 54.0 million from 56.2 million. Organic growth was about 6.7%, with currency reducing revenue by roughly 0.7%.

Margin pressure came from higher sales and marketing and G&A spending, including a $3.9 millionc loss from a freight payment service provider bankruptcy and higher personnel costs tied to the North American sales force expansion. Balance sheet and capital allocation shifted meaningfully. IDEXX issued $150 million of senior notes in December 2013 (3.94% due 2023 and 4.04% due 2025), and its credit line balance rose to $277 million, so total debt increased sharply.

Stockholders' equity fell to $518 milliond from $636 million because buybacks ($372 million charged to equity) exceeded earnings retention. Cash rose to $279 million, but about $278 million of it sits in foreign subsidiaries, and the company's effective tax rate fell to 28.7% from 31.6%, partly due to a one-time R&D credit recognized in 2013. Management also flagged that the U.S. R&D credit expired again on January 1, 2014, and that interest expense will rise in 2014.

The business faces ongoing concentration and competitive risks. Two distributors, Henry Schein (9% of revenue) and MWI (8%), account for a meaningful share of sales, and the FTC consent order limits exclusive distribution arrangements. Corporate hospital consolidation and competitors such as VCA Antech and Abaxis are pressuring the market.

Management guided to a 2014 capital expenditure plan of about $80 million and to a roughly $10 million revenue headwind from lower European bovine testing volumes. Overall, the filing describes a company with strong recurring-revenue economics and rising capital returns, but with more leverage, a thinner margin trend, and tax-rate tailwinds that are unlikely to repeat.

Key Highlights

  1. Revenue grew 6.5% to $1,377.1 million (organic growth ~6.7%), with CAG up 7.3% to $1,150.2 million and recurring diagnostic revenue up 8.7% to $974.0 million, about 71% of total revenue.
  2. Operating income rose only 1.6% to $266.8 million, and operating margin declined to 19.4% from 20.3% due to higher sales/marketing (+12.2%) and G&A (+14.7%) spending, plus a $3.9 million freight service provider loss.
  3. Diluted EPS increased 9.8% to $3.48 from $3.17, supported by a 5.6% reduction in diluted share count after $367.8 million of share repurchases (3.95 million shares at an average $93.06).
  4. Total debt rose sharply: $150 million of senior notes issued in December 2013 plus $277 million drawn on the $450 million credit facility, which lifted long-term debt to $150.4 million and interest expense to $5.4 million from $3.8 million.
  5. Stockholders' equity declined to $518.2 million from $636.3 million as buybacks outpaced earnings retention, and the company has never paid a cash dividend.
  6. Effective tax rate fell to 28.7% from 31.6%, aided by a retroactive 2012 R&D credit, but the U.S. R&D credit expired again on January 1, 2014, which is a headwind for 2014 earnings.
  7. About $278.1 million of the $279.1 million cash balance is held by foreign subsidiaries, and about 42% of revenue came from customers outside the U.S., creating currency and repatriation exposure.

Follow one dollar

Of each $1.00 of revenue in FY2013, IDEXX Laboratories kept $0.14.

  1. Revenue$1.38B100.0%
  2. Cost of revenue−$620.9M45.1%
  3. Gross profit$756.1M54.9%
  4. Operating costs−$489.4M35.5%
  5. Operating income$266.8M19.4%
  6. Interest, other & tax−$79.0M5.7%
  7. Net income$187.8M13.6%
Computed from 10-KFY2013filed February 18, 2014Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2013 revenue went

$1.38B
  • Cost of revenue: $620.9M, 45% of revenue
  • Other operating costs: $401.4M, 29% of revenue
  • Net income: $187.8M, 14% of revenue
  • R&D: $88.0M, 6.4% of revenue
  • Interest, other & tax: $79.0M, 5.7% of revenue

Kept 14% as net income

Full revenue history →

Financial Statements

FY2013 against FY2012

Line itemFY2013FY2012Change
Revenue$1.38B$1.29B+6.5%
Cost of Revenue$620.94M$594.19M+4.5%
Gross Profit$756.12M$699.15M+8.1%
R&D Expenses$88.00M$82.01M+7.3%
Operating Income$266.76M$262.56M+1.6%
Interest Expense$5.39M$3.85M+40.0%
Net Income$187.80M$178.27M+5.3%
EPS (Basic)$1.77$1.62+9.3%
EPS (Diluted)$1.74$1.58+9.8%
Shares Outstanding (Basic)106.32M109.97M−3.3%
Shares Outstanding (Diluted)107.97M112.31M−3.9%

Frequently Asked Questions

  1. What drove IDEXX's revenue growth in 2013, and how sustainable is it?

    Growth was driven mainly by CAG recurring revenue: VetLab consumables rose 11.7%, reference laboratory services rose 8.3%, and rapid assays rose 4.5%. Increased testing volumes from new customers and installed-base growth from Catalyst Dx and ProCyte Dx instruments were key, along with price increases. The recurring revenue model (consumables, reference lab tests, SNAP tests) provides a durable base, but management notes that instrument placements are declining for VetTest and LaserCyte lines and that economic weakness in Europe continues to weigh on demand.

  2. Why did operating income grow much more slowly than revenue?

    Operating expenses grew 12.1%, faster than revenue. Sales and marketing rose $26.5 million (mainly personnel costs from the North American sales force reorganization and expansion), and G&A rose $20.3 million (including IT investment, the freight service company loss, and Brazilian distributor acquisition costs). LPD segment operating income also fell 32% due to lower BSE test volumes and a lower gross margin.

  3. How did IDEXX's capital structure change, and does it raise financial risk?

    IDEXX moved from low debt (about $1.4 million of long-term debt in 2012) to about $427 million of total debt after issuing $150 million of fixed-rate senior notes and increasing borrowings on the revolving credit facility to $277 million. Management says it is in compliance with covenants, with a maximum leverage ratio of 3.5x on the notes and 3.0x on the credit facility. Leverage remains moderate, but the increase reduces financial flexibility, and the company expects higher interest expense in 2014. Share buybacks of $367.8 million in 2013 were largely funded by debt and operating cash flow of $246.0 million.

  4. What are the main risks to IDEXX's business highlighted in the filing?

    Key risks include concentration among U.S. distributors (Henry Schein 9% and MWI 8% of 2013 revenue), a 2013 FTC consent order that limits exclusive distribution arrangements, and increasing consolidation of corporate veterinary hospitals (e.g., Banfield, VCA Antech) and buying groups that could shift purchasing to competitors. Other risks include dependence on sole-source suppliers (e.g., Ortho for chemistry slides), regulatory approvals from USDA, FDA, and EPA, competition from better-funded rivals, a limited scale in the human point-of-care market, international currency exposure, and possible cybersecurity or disaster-related disruptions to a single Westbrook, Maine manufacturing site.